Patents by Inventor Hyo-Kyung HAN

Hyo-Kyung HAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Display device
    Patent number: 11967267
    Abstract: Provided is a display device including a display panel, an optical sensor, a timing controller, a scan driver, a data driver, and an image controller. The timing controller controls an image refresh rate of the display panel based on a refresh rate control signal. Thus, the display device provides improved visibility.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: April 23, 2024
    Assignees: Samsung Display Co., Ltd., UNIST (Ulsan National Institute Of Science and Technology)
    Inventors: Hyo Sun Kim, Oh Sang Kwon, Seong Gyu Choe, Chang Yeong Han, Min Kyung Kim, You Ra Kim, Eun Jung Lee, Hyung Suk Hwang
  • Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient
    Patent number: 10766857
    Abstract: The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: September 8, 2020
    Assignees: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Yongseok Choi, Jae-Hong Kim, Kyeong Lee, Hyo-Kyung Han, Jun Dong Wei, Jinsun Kwon, Ja-Il Goo
  • Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient
    Patent number: 10494333
    Abstract: The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.
    Type: Grant
    Filed: July 23, 2016
    Date of Patent: December 3, 2019
    Assignees: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Yongseok Choi, Jae-Hong Kim, Kyeong Lee, Hyo-Kyung Han, Jun Dong Wei, Jinsun Kwon, Ja-Il Goo
  • NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT
    Publication number: 20190071395
    Abstract: The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Yongseok CHOI, Jae-Hong KIM, Kyeong LEE, Hyo-Kyung HAN, Jun Dong WEI, Jinsun KWON, Ja-Il GOO
  • Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient
    Patent number: 10179764
    Abstract: The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.
    Type: Grant
    Filed: July 23, 2016
    Date of Patent: January 15, 2019
    Assignees: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Yongseok Choi, Jae-Hong Kim, Kyeong Lee, Hyo-Kyung Han, Jun Dong Wei, Jinsun Kwon, Ja-Il Goo
  • NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT
    Publication number: 20180215706
    Abstract: The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.
    Type: Application
    Filed: July 23, 2016
    Publication date: August 2, 2018
    Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Yongseok CHOI, Jae-Hong KIM, Kyeong LEE, Hyo-Kyung HAN, Jun Dong WEI, Jinsun KWON, Ja-ll GOO
  • NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT
    Publication number: 20180201573
    Abstract: The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.
    Type: Application
    Filed: July 23, 2016
    Publication date: July 19, 2018
    Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Yongseok CHOI, Jae-Hong KIM, Kyeong LEE, Hyo-Kyung HAN, Jun Dong WEI, Jinsun KWON, Ja-Il GOO